Dynamic CEA kinetics as a prognostic biomarker for HER2-negative advanced gastric cancer treated with chemoimmunotherapy.

BMC Cancer · 2025 · PMC12681174 · PMID 41350672

Europe PMC DOI

hedged sentence

0.2450

closest p · 4.9× alpha

0.2450

boldest claim

The sentences

did not reach statistical significanceP = 0.245not close (p > 0.1)

While there was a trend towards better overall survival in the Slow-riser group, the difference in mOS did not reach statistical significance (16.3 months; 95% CI, 13.5–19.1 vs. 12.7 months; 95% CI, 9.8–15.6; P = 0.245).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.